Summary Globally, acne vulgaris was responsible for 4·96 million (95% UI 2·98–7·85) DALYs in 2019. Of these, 3·52 million (2·11–5·64) DALYs occurred in those ages 15–49 years old.

Definition Acne vulgaris (or acne) is a chronic inflammatory disease of the pilosebaceous unit associated with an increase in sebum secretion (ICD-10: L70, excluding L70.4).

Total sources
Incidence 0
Prevalence 90
Remission 0
Causes of death 0
Other 15
Table 1: Total sources used in GBD 2019 estimation
What is new in GBD 2019?
  • •Instead of DisMod-MR, MR-BRT was used to adjust outpatient data (and data that were not based on physical exams) toward the level of other prevalence datapoints, which were more representative of the general population.
  • •Data for both sexes combined and large age categories were assigned to sex-specific and more fine-grained age categories.
  • •New data from Poland (2015–2017) and USA claims data (2015–2016) were incorporated into the model.
Prevalence
Incidence
Deaths
YLLs
YLDs
DALYs
Cases
(millions)
Rate (per 100 000)
Cases
(millions)
Rate (per 100 000)
Deaths
(millions)
Rate (per 100 000)
YLLs
(millions)
Rate (per 100 000)
YLDs
(millions)
Rate (per 100 000)
DALYs
(millions)
Rate (per 100 000)
2019
Both Sexes
231
(208
to 255)
3073·3
(2761·6
to 3403·1)
117
(103
to 134)
1585·9
(1384·8
to 1812·2)
-–
-–
-–
-–
4·96
(2·98
to 7·85)
65·9
(39·6
to 104·4)
4·96
(2·98
to 7·85)
65·9
(39·6
to 104·4)
Females
129
(116
to 141)
3485·9
(3143·8
to 3846·4)
65·0
(57·2
to 73·7)
1796·0
(1570·8
to 2045·9)
-–
-–
-–
-–
2·75
(1·65
to 4·34)
74·5
(44·8
to 117·9)
2·75
(1·65
to 4·34)
74·5
(44·8
to 117·9)
Males
103
(91·8
to 114)
2675·9
(2392·9
to 2978·7)
52·4
(45·9
to 59·9)
1384·9
(1206·7
to 1586·9)
-–
-–
-–
-–
2·21
(1·32
to 3·51)
57·6
(34·4
to 91·6)
2·21
(1·32
to 3·51)
57·6
(34·4
to 91·6)
Percentage change 2010-19
Both Sexes
8·2%
(7·8
to 8·7)
4·1%
(3·6
to 4·6)
9·8%
(9·0
to 10·6)
4·9%
(4·2
to 5·6)
-–
-–
-–
-–
8·2%
(7·4
to 8·9)
4·1%
(3·3
to 4·8)
8·2%
(7·4
to 8·9)
4·1%
(3·3
to 4·8)
Females
7·5%
(6·9
to 8·1)
3·3%
(2·7
to 3·9)
9·3%
(8·3
to 10·3)
4·3%
(3·5
to 5·2)
-–
-–
-–
-–
7·4%
(6·5
to 8·3)
3·3%
(2·4
to 4·1)
7·4%
(6·5
to 8·3)
3·3%
(2·4
to 4·1)
Males
9·2%
(8·5
to 9·8)
5·2%
(4·4
to 5·8)
10·4%
(9·5
to 11·3)
5·6%
(4·7
to 6·4)
-–
-–
-–
-–
9·1%
(8·1
to 10·2)
5·1%
(4·0
to 6·1)
9·1%
(8·1
to 10·2)
5·1%
(4·0
to 6·1)
Numbers in parentheses are 95% uncertainty intervals.
Table 2: Global prevalence, incidence, deaths, YLLs, YLDs, and DALYs in counts and age-standardised rates for both sexes combined, females, and males, 2019, with percentage change between 2010 and 2019
Deaths YLLs YLDs DALYs
1990 -- -- 42nd 95th
2010 -- -- 37th 87th
2019 -- -- 37th 83rd
Table 3: Rank among Level 3 causes for global deaths, YLLs, YLDs, and DALYs in 1990, 2010, and 2019, for both sexes combined
Figure 1: Composition of DALYs by constituent sequelae YLDs for both sexes combined, 2019
No Legend
Figure 2: Age-standardised DALY rates for each location by SDI, both sexes combined, 2019
Figure 3: Composition of DALYs by YLLs and YLDs, age group, and sex, 2019
No Legend
Figure 4: Age-standardised DALY rates (per 100 000) by location, both sexes combined, 2019